Family physicians, specialists and allied health professionals.
Program AccessListen Now
Heart failure with preserved EF (HFpEF) carries substantial morbidity and mortality, yet evidence-based treatments to improve outcomes are sorely lacking. Recently, the FDA made the unusual decision to approve
sacubitril/valsartan for HFpEF despite a neutral trial with this agent. Similarly, while spironolactone’s major trial in HFpEF was not positive, guidelines have endorsed this therapy based on sub-group analyses. This podcast will explore why these decisions were made and whether these treatments should be considered for HFpEF patients.
- To review current treatment strategies for HFpEF
- To understand how neutral trials may still influence guidelines and practice
This program is NOT accredited.
Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio.Back To Programs
Mar. 19, 2020
BECOME A CCRN MEMBER
Being a part of CCRN has benefits